Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study

Area of Science:

• Metabolomics
• Endocrinology
• Preventive Medicine

Background:

• Acylcarnitines were previously suggested as early biomarkers for metabolic dysfunction.
• Their independent predictive value for type 2 diabetes (T2D) in humans remained unclear.

Purpose of the Study:

• To investigate if acylcarnitines can independently predict incident type 2 diabetes.
• To assess the incremental predictive value of acylcarnitines when combined with traditional risk factors.

Main Methods:

• A population-based prospective study involving 2,103 Chinese adults (aged 50-70).
• Targeted metabolic profiling of plasma acylcarnitines using liquid chromatography-tandem mass spectrometry at baseline.
• Follow-up for 6 years to ascertain diabetes incidence, alongside collection of conventional risk factors.

Main Results:

• Over 6 years, 507 participants developed T2D.
• A panel of acylcarnitines, especially long-chain variants, showed significant association with increased T2D risk.
• The full predictive model including acylcarnitines demonstrated a substantial improvement in predicting diabetes (AUC 0.89 vs. 0.73).

Conclusions:

• Acylcarnitines, linked to mitochondrial lipid metabolism, significantly enhance T2D prediction beyond conventional factors.
• These findings highlight acylcarnitines as potential early biomarkers for T2D risk.
• Further research is needed to validate these findings in diverse populations and elucidate underlying mechanisms.